Stay updated with breaking news from Hyperoxaluria Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Primary Hyperoxaluria Treatment MarketThe global primary hyperoxaluria treatments market is expected to develop at a compound annual growth rate (CAGR) of 8.6% between 2023 and 2033, according to a recent market research analysis by Future Market Insights. By the end of the forecast year previously indicated, the ma...
Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.
According to a new market research report published by Future Market Insights, the global Primary Hyperoxaluria Treatment Market is expected to grow at a CAGR of 8.6% during the forecast period of 2023 to 2033. The market is expected to surpass US$ 41 million in value terms by the end of the aforementioned forecast...
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie
The FDA approved Alnylam’s Oxlumo for an expanded indication, rare disease PH1, with the label to include patients with the most severe kidney impairment.